Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Zanzalintinib (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Colon cancer; Colorectal cancer; Prostate cancer; Rectal cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms STELLAR-001
  • Sponsors Exelixis

Most Recent Events

  • 11 Feb 2025 According to an Exelixis media release, the company anticipates disclosing additional data from zanzalintinibs phase 1b/2 studies in the first half of 2025.
  • 25 Jan 2025 Results from cohort (n=107) in patients with previously treated metastatic colorectal cancer, presented in an Exelixis media release
  • 25 Jan 2025 According to an Exelixis media release, results from an expansion cohort of this phase 1b/2 STELLAR-001 trial, will be presented during Poster Session C: Cancers of the Colon, Rectum and Anus, at 7:00 a.m. PT on January 25 at the American Society of Clinical Oncology 2025 Gastrointestinal Cancers Symposium (ASCO GI 2025).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top